These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3240762)

  • 1. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene.
    Heimsoth V; Loew D; Schuster O
    Eur J Drug Metab Pharmacokinet; 1988; 13(3):161-4. PubMed ID: 3240762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
    Loew D; Barkow D; Schuster O; Knoell HE
    Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults.
    van Meyel JJ; Tan Y; Smits P; Russel FG; van Ginneken CA; Gribnau FW
    Eur J Clin Pharmacol; 1990; 39(6):595-7. PubMed ID: 2095345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene.
    Priewer H; Kraft H; Mutschler E
    Arzneimittelforschung; 1985; 35(11):1688-91. PubMed ID: 4091871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination.
    Lammintausta R; Anttila M; Viinamäki O
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):395-8. PubMed ID: 7005123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Localization of the action of furosemide and triamterene in the nephron by means of correlating their pharmacokinetics and pharmacodynamics].
    Lebedev AA; Munina II
    Farmakol Toksikol; 1989; 52(1):44-7. PubMed ID: 2707420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An experimental and clinical pharmacological study of the influence of triamterene on the diuretic and saluretic properties of furosemide xantinol].
    Celdrán E; Bekett PR; Roberts DJ
    Arzneimittelforschung; 1976; 26(11):2073-6. PubMed ID: 14648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers.
    Levinson B; Shenouda M; Stypinski D
    Int J Clin Pharmacol Ther; 2005 Feb; 43(2):92-100. PubMed ID: 15726878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacodynamic and pharmacokinetic characteristics of furosemide and furesis].
    Noskov VB; Goncharov IB; Kovachevich IV; Kodratenko SN; Starodubtsev AK; Sokolova EV
    Eksp Klin Farmakol; 1999; 62(3):32-6. PubMed ID: 10439945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of magnesium sparing effect of a single dose of triamterene in combination with frusemide in healthy male adults.
    van Meyel JJ; Smits P; Gribnau FW
    Br J Clin Pharmacol; 1990 Nov; 30(5):774-7. PubMed ID: 2271378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, natriuretic, antikaliuretic and antimagnesiuretic properties of an acidic triamterene derivative.
    Netzer T; Ullrich F; Majewski M; Mutschler E
    Arzneimittelforschung; 1992 Jun; 42(6):807-11. PubMed ID: 1418034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of heart failure with combined furosemide retard/triamterene].
    Burkhardt H; Graul EH; Pfab R; Schuster O; Loew D
    Fortschr Med; 1984 Jul; 102(27-28):735-9. PubMed ID: 6479817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of a combination of furosemid retard and triamteren in congestive edema].
    Jablonski K; Tronnier H
    Med Welt; 1984 Feb; 35(5):160-2. PubMed ID: 6700429
    [No Abstract]   [Full Text] [Related]  

  • 17. [Animal experimental and human pharmacologic studies with phase-II metabolites of triamterene].
    Völger KD
    Arzneimittelforschung; 1991 May; 41(5):499-506. PubMed ID: 1898420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of amiloride and triamterene on urinary magnesium excretion in conscious saline-loaded rats.
    Devane J; Ryan MP
    Br J Pharmacol; 1981 Feb; 72(2):285-9. PubMed ID: 7214099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects.
    Abou-Auda HS
    Int J Clin Pharmacol Ther; 1998 May; 36(5):275-81. PubMed ID: 9629992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.